Bureau Veritas


Estimates maintained

05/05/21 -"The target price is practically unchanged following the Q1 21 revenue release. The catch-up of postponed audits and inspections supported growth in Q1 21 and came to an end in March 2021. Q2 21 ..."

Pages
52
Language
English
Published on
05/05/21
You may also be interested by these reports :
26/04/24
SGS began the year with good organic growth in revenues, even though the yoy growth was heavily impacted by FX headwinds. Organic growth was higher ...

26/04/24
Bureau Veritas started the year with an organic growth beat vs. the company-compiled consensus, even though the absolute numbers were in line. FX was ...

24/04/24
Eurofins Scientific reported a Q1 2024 trading update slightly below the street’s expectations. While organic sales growth in the core business ...

23/04/24
Randstad was impacted by tough market conditions in all its geographies. Organic revenue per working day decreased by -7.8%. North America and ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO